|
1
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Correa P: Gastric cancer: Two epidemics?
Dig Dis Sci. 56:1585–1586, author reply 1586. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Salvon-Harman JC, Cady B, Nikulasson S,
Khettry U, Stone MD and Lavin P: Shifting proportions of gastric
adenocarcinomas. Arch Surg. 129:381–388, discussion 388–389. 1994.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Bilici A: Treatment options in patients
with metastatic gastric cancer: Current status and future
perspectives. World J Gastroenterol. 20:3905–3915. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Akama Y, Yasui W, Yokozaki H, Kuniyasu H,
Kitahara K, Ishikawa T and Tahara E: Frequent amplification of the
cyclin E gene in human gastric carcinomas. Jpn J Cancer Res.
86:617–621. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Bani-Hani KE, Almasri NM, Khader YS,
Sheyab FM and Karam HN: Combined evaluation of expressions of
cyclin E and p53 proteins as prognostic factors for patients with
gastric cancer. Clin Cancer Res. 11:1447–1453. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Sun Y, Li JY, He JS, Zhou LX and Chen K:
Tissue microarray analysis of multiple gene expression in
intestinal metaplasia, dysplasia and carcinoma of the stomach.
Histopathology. 46:505–514. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Takano Y, Kato Y, van Diest PJ, Masuda M,
Mitomi H and Okayasu I: Cyclin D2 overexpression and lack of p27
correlate positively and cyclin E inversely with a poor prognosis
in gastric cancer cases. Am J Pathol. 156:585–594. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Shan YS, Hsu HP, Lai MD, Hung YH, Wang CY,
Yen MC and Chen YL: Cyclin D1 overexpression correlates with poor
tumor differentiation and prognosis in gastric cancer. Oncol Lett.
14:4517–4526. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Okamoto K, Tajima H, Ohta T, Nakanuma S,
Hayashi H, Nakagawara H, Onishi I, Takamura H, Ninomiya I, Kitagawa
H, et al: Angiotensin II induces tumor progression and fibrosis in
intrahepatic cholangiocarcinoma through an interaction with hepatic
stellate cells. Int J Oncol. 37:1251–1259. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Du N, Feng J, Hu LJ, Sun X, Sun HB, Zhao
Y, Yang YP and Ren H: Angiotensin II receptor type 1 blockers
suppress the cell proliferation effects of angiotensin II in breast
cancer cells by inhibiting AT1R signaling. Oncol Rep. 27:1893–1903.
2012.PubMed/NCBI
|
|
12
|
Kinoshita J, Fushida S, Harada S, Yagi Y,
Fujita H, Kinami S, Ninomiya I, Fujimura T, Kayahara M, Yashiro M,
et al: Local angiotensin II-generation in human gastric cancer:
Correlation with tumor progression through the activation of
ERK1/2, NF-kappaB and survivin. Int J Oncol. 34:1573–1582. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Matsuyama M, Funao K, Kuratsukuri K,
Tanaka T, Kawahito Y, Sano H, Chargui J, Touraine JL, Yoshimura N
and Yoshimura R: Telmisartan inhibits human urological cancer cell
growth through early apoptosis. Exp Ther Med. 1:301–306. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Koyama N, Nishida Y, Ishii T, Yoshida T,
Furukawa Y and Narahara H: Telmisartan induces growth inhibition,
DNA double-strand breaks and apoptosis in human endometrial cancer
cells. PLoS One. 9:e930502014. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Kozako T and Soeda S, Yoshimitsu M, Arima
N, Kuroki A, Hirata S, Tanaka H, Imakyure O, Tone N, Honda S and
Soeda S: Angiotensin II type 1 receptor blocker telmisartan induces
apoptosis and autophagy in adult T-cell leukemia cells. FEBS Open
Bio. 6:442–460. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Fujihara S, Morishita A, Ogawa K, Tadokoro
T, Chiyo T, Kato K, Kobara H, Mori H, Iwama H and Masaki T: The
angiotensin II type 1 receptor antagonist telmisartan inhibits cell
proliferation and tumor growth of esophageal adenocarcinoma via the
AMPKα/mTOR pathway in vitro and in vivo. Oncotarget. 8:8536–8549.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Oura K, Tadokoro T, Fujihara S, Morishita
A, Chiyo T, Samukawa E, Yamana Y, Fujita K, Sakamoto T, Nomura T,
et al: Telmisartan inhibits hepatocellular carcinoma cell
proliferation in vitro by inducing cell cycle arrest. Oncol
Rep. 38:2825–2835. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Samukawa E, Fujihara S, Oura K, Iwama H,
Yamana Y, Tadokoro T, Chiyo T, Kobayashi K, Morishita A, Nakahara
M, et al: Angiotensin receptor blocker telmisartan inhibits cell
proliferation and tumor growth of cholangiocarcinoma through cell
cycle arrest. Int J Oncol. 51:1674–1684. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Okazaki M, Fushida S, Harada S, Tsukada T,
Kinoshita J, Oyama K, Tajima H, Ninomiya I, Fujimura T and Ohta T:
The angiotensin II type 1 receptor blocker candesartan suppresses
proliferation and fibrosis in gastric cancer. Cancer Lett.
355:46–53. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Karimi P, Islami F, Anandasabapathy S,
Freedman ND and Kamanqar F: Gastric cancer: Descriptive
epidemiology, risk factors, screening, and prevention. Cancer
Epidemiol Biomarkers Prev. 5:700–713. 2014. View Article : Google Scholar
|
|
21
|
Wu CY, Wu MS, Kuo KN, Wang CB, Chen YJ and
Lin JT: Effective reduction of gastric cancer risk with regular use
of nonsteroidal anti-inflammatory drugs in Helicobacter
pylori-infected patients. J Clin Oncol. 28:2952–2957. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Epplein M, Nomura AM, Wilkens LR,
Henderson BE and Kolonel LN: Nonsteroidal antiinflammatory drugs
and risk of gastric adenocarcinoma: The multiethnic cohort study.
Am J Epidemiol. 170:507–514. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Freedman ND, Chow WH, Gao YT, Shu XO, Ji
BT, Yang G, Lubin JH, Li HL, Rothman N, Zheng W and Abnet CC:
Menstrual and reproductive factors and gastric cancer risk in a
large prospective study of women. Gut. 56:1671–1677. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
D'Incalci M, Colombo T, Ubezio P,
Nicoletti I, Giavazzi R, Erba E, Ferrarese L, Meco D, Riccardi R,
Sessa C, et al: The combination of yondelis and cisplatin is
synergistic against human tumor xenografts. Eur J Cancer.
39:1920–1926. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Kato K, Gong J, Iwama H, Kitanaka A, Tani
J, Miyoshi H, Nomura K, Mimura S, Kobayashi M, Aritomo Y, et al:
The antidiabetic drug metformin inhibits gastric cancer cell
proliferation in vitro and in vivo. Mol Cancer Ther. 11:549–560.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Cordon-Cardo C: Mutations of cell cycle
regulators. Biological and clinical implications for human
neoplasia. Am J Pathol. 147:545–560. 1995.PubMed/NCBI
|
|
27
|
Hunter T and Pines J: Cyclins and cancer.
II: Cyclin D and CDK inhibitors come of age. Cell. 79:573–582.
1994. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Matsui T, Chiyo T, Kobara H, Fujihara S,
Fujita K, Namima D, Nakahara M, Kobayashi N, Nishiyama N, Yachida
T, et al: Telmisartan inhibits cell proliferation and tumor growth
of esophageal squamous cell carcinoma by inducing s-phase arrest in
vitro and in vivo. Int J Mol Sci. 20:e31972019. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Funao K, Matsuyama M, Kawahito Y, Sano H,
Chargui J, Touraine JL, Nakatani T and Yoshimura R: Telmisartan is
a potent target for prevention and treatment in human prostate
cancer. Oncol Rep. 20:295–300. 2008.PubMed/NCBI
|
|
30
|
Funao K, Matsuyama M, Kawahito Y, Sano H,
Chargui J, Touraine JL, Nakatani T and Yoshimura R: Telmisartan as
a peroxisome proliferator-activated receptor-γ ligand is a new
target in the treatment of human renal cell carcinoma. Mol Med Rep.
2:193–198. 2009.PubMed/NCBI
|
|
31
|
Lee LD, Mafura B, Lauscher JC, Seeliger H,
Kreis ME and Gröne J: Antiproliferative and apoptotic effects of
telmisartan in human colon cancer cells. Oncol Lett. 8:2681–2686.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Mimori K, Mori M, Shiraishi T, Fujie T,
Baba K, Haraguchi M, Abe R, Ueo H and Akiyoshi T: Clinical
significance of tissue inhibitor of metalloproteinase expression in
gastric carcinoma. Br J Cancer. 76:531–536. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Yoshikawa T, Tsuburaya A, Kobayashi O,
Sairenji M and Miyagi Y: Protein levels of tissue inhibitor of
metalloproteinase-1 in tumor extracts as a marker for prognosis and
recurrence in patients with gastric cancer. Gastric Cancer.
9:106–113. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Liao P, Li W, Liu R, Teer JK, Xu B, Zhang
W, Li X, Mcleod HL and He Y: Genome-scale analysis identifies
SERPINE1 and SPARC as diagnostic and prognostic biomarkers in
gastric cancer. OncoTargets Ther. 11:6969–6980. 2018. View Article : Google Scholar
|
|
35
|
Hsieh AC and Moasser MM: Targeting HER
proteins in cancer therapy and the role of the non-target HER3. Br
J Cancer. 97:453–457, 20017. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Masaki T, Hatanaka Y, Nishioka M, Tokuda
M, Shiratori Y, Reginfo W and Omata M: Activation of epidermal
growth factor receptor kinase in gastric carcinoma: A preliminary
study. Am J Gastroenterol. 95:2135–2136. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Huang Z, Zhu D, Wu L, He M, Zhou X, Zhang
L, Zhang H, Wang W, Zhu J, Cheng W, et al: Six serum-based miRNAs
as potential diagnostic biomarkers for gastric cancer. Cancer
Epidemiol Biomarkers Prev. 26:188–196. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Ren L, Li F, Di M, Fu Y, Hui Y, Xiao G,
Sun Q, Liu Y, Ren D and Du X: MicroRNA-187 regulates gastric cancer
progression by targeting the tumor suppressor CRMP1. Biochem
Biophys Res Commun. 482:597–603. 2017. View Article : Google Scholar : PubMed/NCBI
|
